Preclinical evaluation of a novel membrane-intercalating agent shows antibacterial activity with no generation of bacterial resistance. Membrane fluidity is key to the function of prokaryotic and eukaryotic cells. Natureza Products, Inc has developed chitosan-coated esters of dodecanoic acid as membrane intercalating agents with anti-inflammatory and antibacterial properties. These can be targeted to Gram-positive or negative bacteria by alteration of charge and decoration on the chitosan coat, and bacteria show no innate or evolved resistance to these agents on exposure. [read more]

Natureza Develops a Patented Transformative New Class of Antibotic Agents that Overcome Bacterial Resistance. This work identifies a transformative new class of antibiotics with the novel property of lack of bacterial resistance. [read more]

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics. [read more]

The WHO has recognised a number of antibiotic-resistant pathogens as posing the greatest threat to human health. It further concluded that mortality and morbidity from resistant infections is on the rise globally, the clinical anti-bacterial pipeline remains insufficient, and the pipeline outlook remains bleak (WHO 2019). [read more]